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The plasma membrane calcium ATPases (PMCA) are a family of genes which extrude Ca2+ from the cell and are involved in 
the maintenance of intracellular free calcium levels and/or with Ca2+ signalling, depending on the cell type. In the cardiovas-
cular system, Ca2+ is not only essential for contraction and relaxation but also has a vital role as a second messenger in signal 
transduction pathways. A complex array of mechanisms regulate intracellular free calcium levels in the heart and vasculature 
and a failure in these systems to maintain normal Ca2+ homeostasis has been linked to both heart failure and hypertension. This 
article focuses on the functions of PMCA, in particular isoform 4 (PMCA4), in the heart and vasculature and the reported links 
between PMCAs and contractile function, cardiac hypertrophy, cardiac rhythm and sudden cardiac death, and blood pressure 
control and hypertension. It is becoming clear that this family of calcium extrusion pumps have essential roles in both cardio-
vascular health and disease. 
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1  Introduction: The need to develop new 
treatment strategies for heart failure 
It is well established that diseases of the cardiovascular sys-
tem are the world’s largest killers. The World Health Or-
ganisation reports that currently 17.1 million deaths a year 
are attributed to these diseases, and the number is set to rise. 
This group of diseases which includes hypertension, stroke, 
coronary heart disease, heart failure, cardiomyopathies, 
rheumatic and congenital heart disease, and peripheral vas-
cular disease are not only prevalent in western countries, 
with approximately one in three deaths in the USA resulting 
from cardiovascular disease (CVD), but are fast becoming a 
very major health concern in the developing world. Alt-
hough deaths from several of these CVDs are reducing year 
on year, deaths as a result of heart failure (HF) are increas-
ing largely because the prevalence of HF increases sharply 
with age. The proportion of the population classified as el-
derly (>60 years) is the fastest growing age group across the 
world; for example, in western countries it is estimated that 
by 2050 approximately a quarter of the population will be 
older than 60. 
The life time risk of developing this chronic disease 
reaches one in five, and unlike a number of cardiovascular 
diseases the risk is equal in both men and women [1]. Heart 
failure is a syndrome associated with high rates of morbidi-
ty and mortality with only 35% of patients surviving five 
years post-diagnosis [2]; this outcome impacts not only on 
individual human health but causes an increasing financial 
burden on the health and welfare system. It is therefore es-
sential that we continue to improve our understanding of the 
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molecular mechanisms and intracellular signalling pathways 
underlying the progression of heart failure in order to in-
form our development of new, more effective treatment 
strategies.  
1.1  Alterations in calcium homeostasis are associated 
with heart failure 
Heart failure is a complex syndrome often associated with 
cardiac hypertrophy and subsequent chamber dilation, re-
duced contractile function, altered myocardial energetics, 
and changes to cellular calcium cycling. Hence, the mecha-
nisms governing the Ca2+ transient have been investigated 
in detail [3]. Cardiac excitation-contraction (E-C) coupling 
involves a tightly regulated sequential series of events 
which results in the cyclical increase in free intracellular 
Ca2+ ([Ca2+]i) from 100 nmol L
−1 to 1 μmol L−1. Following 
depolarisation of the plasma membrane, contraction is initi-
ated when Ca2+ enters the cell through the L-type Ca2+ 
channel triggering the release of Ca2+ from the sarcoplasmic 
reticulum (SR) via the ryanodine receptors. Both Ca2+ influx 
and release from the SR lead to an increase in [Ca2+]i, which 
subsequently activates Ca2+-sensitive contractile proteins and 
elicits muscle contraction. Cardiac relaxation requires Ca2+ 
removal from the cytoplasm by four different molecules, the 
sarcoplasmic reticulum Ca2+ ATPase (SERCA), Na+/Ca2+ 
exchanger (NCX), plasma membrane Ca2+/calmodulin de-
pendent ATPase (PMCA) and to a lesser extent the mito-
chondrial Ca2+ uniporter. 
Alterations in calcium homeostasis during excita-
tion-contraction coupling have been recognised in many 
studies associated with heart failure [4–6], and numerous 
genes involved in calcium homeostasis have been reported 
to be altered in heart failure. For example, many studies 
show the downregulation of SERCA in both animal models 
[7] and human tissue samples from failing heart [8]. Borlak 
and Thum [9] have shown that in human end stage heart 
failure, left ventricular expression of PMCA1, PMCA4, and 
SERCA2 is reduced to 30%, 50%, and 30%, respectively, 
compared with the controls. Additionally, an alteration in 
ryanodine receptor (RyR) expression has been associated 
with heart failure [10], and increased expression of NCX 
has been observed in some heart failure models, which is 
thought to be a compensatory mechanism for SERCA 
downregulation [11].  
Of this array of Ca2+ handling mechanisms this review 
will focus on the PMCA and its role in cardiovascular func-
tion. 
2  The plasma membrane calcium ATPases 
(PMCAs) 
The plasma membrane calcium ATPases are ATP-consuming 
calmodulin-dependent pumps which eject Ca2+ into the ex-
tracellular space [12,13]. There are four isoforms of PMCA 
(PMCA1–4; gene names atp2b1–4), each encoded by an 
independent gene, on different chromosomes [14,15]. 
PMCAs are 134 kD proteins which belong to the P-type 
ATPase family of proteins. All four proteins have a similar 
structure comprising 10 transmembrane (TM) domains and 
four major intracellular regions: The N-terminal region is a 
region of low sequence similarity between the four isoforms 
(56.6% homology at the protein level in human genes) and 
its function has not been fully elucidated; the loop between 
TM domains 2 and 3 is involved in calcium pore function; 
whilst the very large loop between TM domains 4 and 5 is 
the site of ATP binding and contains the aspartate residue 
which is phosphorylated during the calcium transport cycle; 
finally the C-terminal tail contains the calmodulin binding 
domain (CaM-BD) which is essential in the regulation of 
pump activity. Binding of the CaM-BD to regions on the 
two large intracellular loops leads to autoinhibition of the 
pump and this inhibitory effect is released upon binding of 
calmodulin to the CaM-BD [16–18]. 
Essentially, PMCA is ubiquitously expressed in that all 
cells express at least one isoform of PMCA and it is hy-
pothesised that the presence of the different isoforms and 
their numerous splice variants [19] reflects the specific and 
differing Ca2+ requirements in different cell types. Thus, it is 
likely that each isoform serves different functions in different 
tissues with specificity being mediated by tissue-specific 
factors/interaction partners, as with other calcium transport-
ers [18]. 
PMCA1 is widely regarded as the housekeeping isoform 
of this family of genes. A study of mouse embryogenesis 
has revealed that PMCA1 is the isoform expressed earliest 
in development [20]; its expression being ubiquitous in both 
the embryo and the adult mouse. Gene knockout studies 
corroborate the view that PMCA1 is a housekeeping gene as 
gene deletion in vivo leads to lethality during a very early 
stage of embryonic development [21]. The expression of 
PMCA2 is much more specific, being localised to inner ear 
cilia, Purkinje cells and the mammary gland [22–26]. 
PMCA3 is also expressed in the brain as well as skeletal 
muscle cells and pancreatic islet cells [22,27–29], whilst 
PMCA4 is expressed in a wide range of cell types including 
erythrocytes, platelets, spermatozoa, heart, vascular smooth 
muscle, kidney, skeletal muscle, stomach, intestine and brain 
[21,22,30–35]. 
In recent years this family of genes has been associated 
with a number of very important human diseases. Loss of 
PMCA2 has been associated with hereditary hearing loss 
[24,36] and its overexpression with poor prognosis of breast 
cancer [37]. PMCA4 has been implicated in Long QT syn-
drome which can lead to sudden cardiac death due to ar-
rhythmia [38,39] and there is now an extensive body of ge-
nome-wide association study data indicating single nucleo-
tide polymorphisms (SNP) in the PMCA1 gene as the single 
strongest association with blood pressure variance and hy-
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pertension [40–43]. These findings provide compelling evi-
dence of the essential roles of the PMCAs in health and 
disease. 
Much of what is known about the physiological and 
pathophysiological functions of PMCAs comes from the 
study of genetically modified mice; for example, PMCA1 
knockout mice die during very early embryonic develop-
ment revealing the essential role of this calcium pump dur-
ing development [21]. PMCA2 knockout mice, as well as 
spontaneous mouse mutants of PMCA2, exhibit both deaf-
ness and ataxia [44–46]. Deletion of PMCA4 leads to sperm 
immotility and subsequent infertility [21,35] and alterations 
in aspects of platelet function including aggregation [32] 
suggesting that although PMCA4 is essentially ubiquitously 
expressed in the adult mouse its function is highly special-
ised.  
Traditionally the role of the PMCAs in the cardiovascu-
lar system has been understudied; PMCA has long been 
presumed to have a minor role in contraction/relaxation.  
However, over recent years, work from our own group and 
others, with a focus on gene knockout and transgenic stud-
ies, has revealed the critical importance of PMCAs in key 
cardiac and vascular functions.  
3  PMCA in the heart 
In the heart two isoforms of PMCA are expressed, PMCA1 
and PMCA4; there is also some evidence that PMCA2 is 
expressed at a low level [28] although not in the cardio- 
myocytes. In non-excitable cells, the primary function of 
PMCA is to expel calcium from the cytosol, but it is clear 
from our work and that of others, that in the heart many of 
the actions of PMCA4 are not as a direct result of its role in 
the maintenance of intracellular calcium levels and its ac-
tion as a bulk calcium extrusion pump [33,47,48]. It is as a 
signalling molecule that PMCA4 is involved in the modula-
tion of physiological and pathophysiological cardiac func-
tions including the β-adrenergic contractile response, cardi-
ac rhythm/rhythm disorders, as well as chronic processes 
such as hypertrophy [33,38,39,47,48] (Figure 1). 
3.1 PMCA4 and β-adrenergic responsiveness in the 
heart 
In recent years, it has become clear that neuronal nitric ox-
ide synthase (nNOS) is a key regulator of heart function 
which is needed to sustain the cardiac β-adrenergic response, 
prevent remodelling after myocardial infarction, and to reg-
ulate oxygen radical production [49–53]. As a consequence, 
the question as to which are the regulators of nNOS has 
become an area of major interest in HF research. In a series 
of publications it has been demonstrated that PMCA4 is 
such a regulator of nNOS. A number of years ago our own 
group identified that PMCA4 binds to nNOS, via a PDZ 
domain, and subsequently tightly regulates nNOS activity; 
this interaction and regulation occurs both in vitro and in 
vivo in the heart [33,47,54,55]. PMCA4 negatively regulates 
nNOS by extruding calcium and thus reducing the [Ca2+]i in 
the vicinity of the PMCA4-nNOS complex and since nNOS  
 
 
Figure 1  PMCA4 has a number of roles in cardiac health and disease. PMCA4, through its interaction with nNOS, regulates β-adrenergic signal transmis-
sion in the heart and influences β-adrenergic responsiveness and cardiac contractility [47]. PMCA4 modulates cardiac hypertrophy through regulation of the 
calcineurin/NFAT signalling pathway [48]. Disruption of a complex formed between PMCA4, nNOS, α1-syntrophin and the voltage gated sodium channel  
Nav1.5 is associated with long QT syndrome [38]. 
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activity is Ca2+/calmodulin dependent this leads to a de-
crease in nNOS activity.  
Mice which overexpress PMCA4 in the heart have re-
cently been shown to display reduced β-adrenergic respon-
siveness in vivo, via an nNOS dependent mechanism 
[33,47]. The PMCA4-nNOS complex controls the cardiac 
β-adrenergic response through a novel signalling pathway. 
PMCA4 inhibits nNOS and thus leads to a reduction in 
nNOS activity. The complex in turn determines local cyclic 
nucleotide concentrations such that a reduction in nNOS 
activity leads to a reduction of cGMP production by soluble 
guanylyl cyclase (sGC). A decrease in the cGMP level re-
sults in the reduction of phosphodiesterase activity, which 
prevents cAMP degradation and hence increased protein 
kinase A (PKA) activity, which ultimately leads to an al-
tered contractile response to β-adrenergic agonists through 
phosphorylation of a number of proteins involved in E-C 
coupling [47]. 
3.2  PMCA4 and cardiac hypertrophy  
It is well established that many proteins that regulate [Ca2+]i 
and Ca2+ signalling in the heart are involved in the cardiac 
hypertrophic response. It has been suggested that stimula-
tors of hypertrophy, such as angiotensin II, noradrenaline 
and aldosterone, cause an increase in the frequency of the 
oscillation rate of the calcium transient. This leads to an 
increase in cell size through the mediation of the calcineu-
rin-NFAT signalling pathway [56], a pathway with ex-
tremely well characterised associations with cardiac hyper-
trophy and heart failure [57].   
PMCA4 has been found to be important in the regulation 
of calcineurin/NFAT signalling; the two proteins bind di-
rectly at the large intracellular loop between TM domains 4 
and 5 of PMCA4 [58]. Calcineurin, which is a serine/      
threonine-specific phosphatase, is activated by a sustained 
increase in [Ca2+]i and an increase in the calcium transient 
[59,60]. Upon activation calcineurin binds to and depho-        
sphorylates NFAT (nuclear factor of activated T-cells) 
which translocates to the nucleus and subsequently activates 
a number of hypertrophic genes [61]. Both in vitro and in 
vivo studies have clearly demonstrated that overexpression 
of PMCA4 inhibits calcineurin which reduces the activation 
of NFAT which in the heart protects against the develop-
ment of pathological hypertrophy [48,58]. 
3.3  PMCA4 and long QT syndrome 
The vast majority of patients with heart failure will die ei-
ther from circulatory insufficiency due to increasing left 
ventricular dysfunction or sudden cardiac death. It is re-
ported that nearly half the deaths from heart failure are 
sudden and are likely caused by ventricular arrhythmia; 
however, the underlying mechanisms are not fully under-
stood. It is also interesting to question why the other 50% do 
not develop lethal ventricular arrhythmias and instead die 
from pump failure despite exposure to similar unspecific 
pro-arrhythmic factors such as fibrosis. Similarly to the 
susceptibility of the myocardium to failure, there may be 
genetic determinants of rhythm disorders. 
As has been described above, PMCA4 forms a complex 
at the plasma membrane with nNOS; in fact this complex 
can exist as part of a larger complex along with 
α1-syntrophin, which binds to PMCA4 via the large intra-
cellular loop between TM domains 4 and 5 [62]. A mutation 
(A390V) in the α1-syntrophin gene, which lies within the 
region which binds to PMCA4, has been associated with 
long QT syndrome [38], a condition associated with sudden 
cardiac death due to arrhythmias. Analysis of the A390V 
mutant shows that it is unable to bind to PMCA4; this re-
sults in enhanced nNOS activity likely because PMCA4 is 
not available to negatively regulate the activity of the en-
zyme. The link between PMCA4 and cardiac rhythm was 
made stronger by the findings of a recent genome wide as-
sociation study which showed that a mutation in CAPON, a 
protein which interacts with PMCA4 and nNOS [63], is 
associated with long QT syndrome and sudden cardiac 
death [39].  
4  PMCA in the vasculature 
In the vasculature both conduit and small resistance arteries 
have been reported to express PMCA1 and PMCA4 [34,64] 
and as such it is possible that both isoforms may modulate 
vascular contractility, vascular structure and thus resistance. 
Recently very strong evidence has emerged that PMCA 
is involved in blood pressure variance and hypertension in 
humans. Hypertension affects around 15% of the general 
population and is strongly associated with heart failure, with 
80% of HF patients having hypertension. Hence, a better 
understanding of the mechanisms regulating blood pressure 
and those underlying the development of hypertension is 
essential if we are to improve treatment strategies for con-
trolling blood pressure and ultimately CVD risk. 
Four independent genome wide association studies 
(GWAS) have established a strong link between the PMCA1 
gene (atp2b1) and blood pressure/hypertension which ap-
pears to be independent of the population/lifestyle because 
the association is similar in White, Japanese and Korean 
populations [40–43]. However, it is evidence from studies 
of PMCA4 that have so far provided clues to the functional 
role the PMCA in regulating vascular tone and blood pres-
sure control. 
4.1  Ca2+ homeostasis in vascular smooth muscle 
Hypertension is associated with a raised peripheral vascular 
resistance and increases in arterial tone as well as structural 
remodelling of resistance arteries [65,66]. The diameter of 
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small arteries, and thus the resistance to flow, is ultimately 
determined by the contractile state of the vascular smooth 
muscle. This in turn is modulated by changes in [Ca2+]i. It 
has long been known that alterations in [Ca2+]i homeostasis 
occur in hypertension [67–69]. 
Vascular smooth muscle contractility is initiated by an 
elevation of [Ca2+]i. [Ca
2+]i may be elevated as a conse-
quence of either influx of Ca2+ across the plasma membrane 
or release of Ca2+ from intracellular stores such as the sar-
coplasmic reticulum (for reviews see [70,71]). The rise in 
[Ca2+]i leads to binding to calmodulin which activates myo-
sin light chain kinase (MLKC) resulting in phosphorylation 
of the regulatory chains of myosin (MLC20) and ultimately 
the formation and cycling of actin-myosin cross-      
bridges to generate contraction. Relaxation generally occurs 
when [Ca2+]i falls and MLC20 is dephosphorylated. Although 
certain stimuli may modulate contractility via effects on the 
Ca2+ sensitivity of the contractile apparatus [72,73] it is 
clear that changes in [Ca2+]i play a direct role in the modu-
lation of smooth muscle, and therefore resistance artery, 
tone. Advancements in cellular imaging, fluorescent probes 
and molecular biology have established the presence of 
subcellular Ca2+ microdomains, signalling compartmentali-
sation and subcellular fluxes within smooth muscle cells 
which can modulate numerous cellular functions including 
contractility in the absence of changes in global [Ca2+]i 
[74–76]. Thus, any agent which modifies Ca2+ homeostasis 
has the potential to alter contractility.  
The [Ca2+]i content of a cell at any one time will be de-
termined by a balance between the activity of the mecha-
nisms which elevate [Ca2+]i (i.e., by movement of Ca
2+ into 
the cell or release of Ca2+ from intracellular stores) and 
those that remove it from the cytoplasm [70,71,77]. Whilst 
the mechanisms responsible for [Ca2+]i elevation in vascular 
smooth muscle have been well characterised, those respon-
sible for decreasing [Ca2+]i to resting levels have received 
less attention.   
Smooth muscle [Ca2+]i is reduced by the action of calci-
um transporters which either extrude Ca2+ out of the cell or 
re-sequester it into intracellular stores [78,79]. These 
mechanisms are important for relaxation, the maintenance 
of low [Ca2+]i  under resting conditions and also to re-load 
intracellular stores with Ca2+. SERCA and the mitochondri-
al uniporter transport Ca2+ into the SR and mitochondria 
respectively while Ca2+ can be transported out of the cell via 
the NCX and by PMCA. Although the NCX is known to be 
the major Ca2+ removal mechanism in other excitable tissues 
such as the heart [80], its involvement in the removal of 
Ca2+ in resistance artery smooth muscle cells has been ques-
tioned [81] thus lending weight to the probability that the 
PMCA is a major route of regulated Ca2+ removal from the 
cytosol. In uterine muscle it has been shown that 70% of 
Ca2+ is extruded from the cell by PMCA4 [82] while in 
bladder 25%–30% is carried out of the cell by PMCAs [83]. 
Taken together this suggests that PMCAs play an important 
role in Ca2+ extrusion in smooth muscles. Modulation of 
PMCA in vascular smooth muscle therefore has the poten-
tial to modulate smooth muscle [Ca2+]i homeostasis and thus 
arterial tone. However, its effects appear complex and are 
not yet entirely understood.  
4.2  PMCA4 and vascular contractility 
Evidence for the role of PMCA4 in the vasculature has 
come largely from the study of transgenic mouse models 
which overexpress PMCA4 in the vascular smooth muscle 
under the control of the SM22α promoter. Contrary to ex-
pectations, these mice were hypertensive suggesting that 
alteration of PMCA4 expression and/or activity may modu-
late blood pressure [84,85]. It was shown that conduit arter-
ies from these mice exhibit enhanced contractility to depo-
larisation and that resistance arteries exhibited heightened 
myogenic responsiveness and increased agonist sensitivity, 
all of which likely play a key role in the observed elevated 
blood pressure [84,85].  
The increased contractility observed with overexpression 
of PMCA4 may at first be surprising. It is logical to hy-
pothesise that overexpression of a calcium extrusion pump 
would reduce [Ca2+]i and thus lower blood pressure due to 
relaxation of the vascular smooth muscle. However, the 
effects observed in the PMCA4 overexpressing mice do not 
appear to involve changes in global [Ca2+]i [85], but levels 
of cGMP, a marker for nNOS activity, are significantly re-
duced [84]. As has been discussed above, in other cell types 
such as cardiomyocytes, PMCA4 plays a more significant 
role in signal transduction through its interaction with and 
regulation of nNOS than in the modulation of Ca2+ 
sub-serving direct excitation contraction coupling. As with 
cardiac myocytes, the effects of PMCA4 on nNOS activity 
may involve changes in sub-cellular Ca2+ homeostasis. It 
appears that such a mechanism may be responsible, in part at 
least, for the enhanced vascular contractility observed with 
overexpression of PMCA4.  
In contrast to studies on transgenic mice it has been 
shown that the PMCA inhibitor caloxin 1c2, which has 10x 
greater affinity for PMCA4 when compared to PMCA1, 2 
or 3, increased coronary artery smooth muscle contractility 
[86]. Studies in cultured vascular smooth muscle cells have 
shown that inhibition of PMCA4 with another PMCA4 in-
hibitor, caloxin 1b1, results in a rise in [Ca2+]i. Thus, both 
inhibition and over-expression of PMCA4 have been re-
ported to increased arterial contractility. 
Taken together this suggests that PMCA4 may modulate 
arterial contractility in different ways which may, or may 
not, involve changes in global [Ca2+]i. It is currently un-
known whether PMCA1 modulates [Ca2+]i and arterial con-
tractility and indeed whether either PMCA1 or PMCA4 
modulates arterial structure. These studies are particularly 
important given the strong association between hyperten-
sion and arterial structure and function. It is perhaps appo-
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site that endothelial nitric oxide synthase, a known major 
determinant of vascular function/dysfunction, has recently 
been found to be negatively regulated by PMCA1 [87]. 
5  Conclusion 
The field of PMCA research, particularly in the cardiovas-
cular research field, has recently made a key transition from 
basic scientific discovery to immediate human relevance in 
key diseases. It is essential that this impetus is maintained 
and that we continue to investigate the functional role of 
this family of genes in order to determine the mechanisms 
underlying major diseases including hypertrophy and heart 
failure, lethal arrhythmias and hypertension. To this end it is 
essential that we identify and develop pharmacological 
agents to specifically inhibit each of the PMCA isoforms 
[88]; the use of such inhibitors as scientific tools would 
greatly enhance this area of research and would inform the 
development of future potential therapeutic reagents.   
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